Key Highlights
BUHLMANN Diagnostics Corp is excited to share highlights from our participation at Digestive Disease Week (DDW) 2024, held May 18-21 in Washington, D.C. Here is a brief overview of our assays offerings and the innovative research we presented.
DDW 2024 Assays Offerings
At BUHLMANN, we offer the broadest range of fecal calprotectin (fCAL) assays in the industry, and we were proud to showcase this line as well as innovative solutions for therapeutic drug monitoring at DDW 2024:
Product Showcased:
- BÜHLMANN fCAL®turbo: An in vitro diagnostic assay intended for the quantitative measurement of fecal calprotectin, a neutrophilic protein that is a marker of intestinal mucosal inflammation in human stool. This FDA 510k-cleared, non-invasive, sensitive, and specific assay is unique in speed, quality, and flexibility. (US:BÜHLMANN fCAL® turbo (K190784): FDA 510(k) cleared. For in vitro Diagnostic Use.BÜHLMANN fCAL® turbo + CALEX® Cap (K191718 & K232057): FDA 510(k) cleared. For in vitro Diagnostic Use.CPT Code: Calprotectin – 83993)
- Quantum Blue® platform offers rapid and quantitative results for serum calprotectin, CRP, serum IFX trough levels, and serum ADL trough levels. (US: Research Use Only. Not for use in diagnostic procedures)
Poster Presentation Highlights:
Comparison of clinical performance of fecal calprotectin of laboratory methods with lateral flow-based POC and home tests
This study evaluated various assay methods (ELISA, PETIA, LFIA) for measuring fecal calprotectin, a crucial biomarker for differentiating Inflammatory Bowel Disease (IBD) from IBS and monitoring mucosal inflammation in Irritable Bowel Syndrome (IBD) patients. The results emphasized the importance of comparable measurements across different technologies.
Poster Presentation Highlights:
Feasibility study of a Point-of-Care assay for rapid determination of anti-TNFα biologics in capillary blood
This study demonstrated the matrix equivalency of capillary blood or EDTA whole blood using rapid tests for ADL and IFX. The findings highlighted the potential for use in a POC setting.
Looking Ahead:
We are thankful to everyone who visited our booth at DDW 2024. BUHLMANN is dedicated to advancing gastroenterology through innovation and collaboration. Stay tuned for more updates and insights from us. We eagerly anticipate seeing you again at the next meeting in 2025!
